Covers all guideline-recommended biomarkers.1
Results in 2 to 3 weeks.1‡
Features a multi-cancer AI-powered scoring algorithm for PD-L1.2§
Medicare coverage for all advanced solid tumors.||
The Guardant360 TissueNext CGP covers clinically relevant biomarkers, including TMB, MSI, and PD-L1.1*
NSCLC guideline-recommended genes are shown in bold.
| Single Nucleotide Variants (SNVs) and Insertions and Deletions (Indels) (84 genes) | Single Nucleotide Variants (SNVs) and Insertions and Deletions (Indels) (84 genes) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKT1 | EGFR | KRAS | PALB2 | ||||||||||
| ALK | ERBB2 | MAP2K1 | PDGFRA | ||||||||||
| APC | ESR1 | MAP2K2 | PIK3CA | ||||||||||
| AR | EZH2 | MAPK1 | PMS2 | ||||||||||
| ARAF | FANCA | MAPK3 | PTEN | ||||||||||
| ARID1A | FBXW7 | MET | PTPN11 | ||||||||||
| ATM | FGFR1 | MLH1 | RAD51D | ||||||||||
| BRAF | FGFR2 | MPL | RAF1 | ||||||||||
| BRCA1 | FGFR3 | MSH6 | RB1 | ||||||||||
| BRCA2 | GATA3 | MSH2 | RET | ||||||||||
| CCND1 | GNA11 | MTOR | RHEB | ||||||||||
| CCND2 | GNAQ | MYC | RHOA | ||||||||||
| CCNE1 | GNAS | MYCN | RIT1 | ||||||||||
| CDH1 | HNF1A | NF1 | ROS1 | ||||||||||
| CDK4 | HRAS | NFE2L2 | SMAD4 | ||||||||||
| CDK6 | IDH1 | NOTCH1 | SMO | ||||||||||
| CDK12 | IDH2 | NPM1 | STK11 | ||||||||||
| CDKN2A | JAK2 | NRAS | TERT** | ||||||||||
| CHEK2 | JAK3 | NTRK1 | TP53 | ||||||||||
| CTNNB1 | KEAP1 | NTRK2 | TSC1 | ||||||||||
| DDR2 | KIT | NTRK3 | VHL | ||||||||||
| AKT1 | CCND2 | ERBB2 | GNAS | MAP2K2 | NF1 | PMS2 | SMAD4 | ||||||
| ALK | CCNE1 | ESR1 | HNF1A | MAPK1 | NFE2L2 | PTEN | SMO | ||||||
| APC | CDH1 | EZH2 | HRAS | MAPK3 | NOTCH1 | PTPN11 | STK11 | ||||||
| AR | CDK4 | FANCA | IDH1 | MET | NPM1 | RAD51D | TERT** | ||||||
| ARAF | CDK6 | FBXW7 | IDH2 | MLH1 | NRAS | RAF1 | TP53 | ||||||
| ARID1A | CDK12 | FGFR1 | JAK2 | MPL | NTRK1 | RB1 | TSC1 | ||||||
| ATM | CDKN2A | FGFR2 | JAK3 | MSH6 | NTRK2 | RET | VHL | ||||||
| BRAF | CHEK2 | FGFR3 | KEAP1 | MSH2 | NTRK3 | RHEB | |||||||
| BRCA1 | CTNNB1 | GATA3 | KIT | MTOR | PALB2 | RHOA | |||||||
| BRCA2 | DDR2 | GNA11 | KRAS | MYC | PDGFRA | RIT1 | |||||||
| CCND1 | EGFR | GNAQ | MAP2K1 | MYCN | PIK3CA | ROS1 | |||||||
| Copy Number Amplifications (CNAs) (20 genes) | Copy Number Amplifications (CNAs) (20 genes) | ||
|---|---|---|---|
| AR | BRAF | ||
| CCND1 | CCND2 | ||
| CCNE1 | CDK4 | ||
| CDK6 | EGFR | ||
| ERBB2 | ESR1 | ||
| FGFR1 | FGFR2 | ||
| KIT | KRAS | ||
| MET | MYC | ||
| MYCN | PDGFRA | ||
| PIK3CA | RAF1 | ||
| AR | BRAF | ||
| CCND1 | CCND2 | ||
| CCNE1 | CDK4 | ||
| CDK6 | EGFR | ||
| ERBB2 | ESR1 | ||
| FGFR1 | FGFR2 | ||
| KIT | KRAS | ||
| MET | MYC | ||
| MYCN | PDGFRA | ||
| PIK3CA | RAF1 | ||
| Fusions (12 genes) | Fusions (12 genes) | ||
|---|---|---|---|
| ALK | MET | ||
| BRAF | NTRK1 | ||
| EGFR | NTRK2 | ||
| FGFR1 | NTRK3 | ||
| FGFR2 | RET | ||
| FGFR3 | ROS1 | ||
| ALK | MET | ||
| BRAF | NTRK1 | ||
| EGFR | NTRK2 | ||
| FGFR1 | NTRK3 | ||
| FGFR2 | RET | ||
| FGFR3 | ROS1 | ||
NEW
Submit samples for processing with as low as 10% tumor fraction.
Testing specifications for Guardant360 TissueNext:
FFPE tissue block or unstained slides
11 slides for tissue CGP only
15 slides for tissue CGP + PD-L1
References: 1. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 2. Guardant Galaxy Flyer. Guardant Health, Inc. Redwood City, CA. 3. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021.